Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

19.0K
Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
19.0K
lncRNA - Long Non-coding RNAs02:39

lncRNA - Long Non-coding RNAs

10.1K
In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...
10.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Chromosome 7 and Haematological Malignancies.

Hematology (Amsterdam, Netherlands)·2016
Same author

RT-PCR Analysis of Breakpoints Involving the MLL Gene Located at 11q23 in Acute Leukemia.

Methods in molecular medicine·2011
Same author

Genetic alteration associated with chronic lymphocytic leukemia.

Cytogenetic and genome research·2007
Same author

Stochastic modelling of apoptosis kinetics.

Apoptosis : an international journal on programmed cell death·2005
Same author

Pk11195, a mitochondrial benzodiazepine receptor antagonist, reduces apoptosis threshold in Bcl-X(L) and Mcl-1 expressing human cholangiocarcinoma cells.

Gut·2002
Same author

The class II tumour suppressor gene RARRES3 maps to 11q12, not 11q23.

Leukemia·2002

Related Experiment Video

Updated: Mar 18, 2026

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

10.0K

Antisense Oligonucleotides: Considerations for Lymphoma Therapy.

F E Cotter1

  • 1a LRF Dept of Haematology and Oncology , Institute of Child Health , 30 Guilford Street, London WC1N 1EH , Tel, Fax, e mail: f.cotter@ich.bpmf.ac.uk.

Hematology (Amsterdam, Netherlands)
|July 14, 2016
PubMed
Summary

Antisense oligonucleotides (ASO) offer a novel approach to treating B-cell lymphomas by targeting specific genes. This therapy aims to induce apoptosis, or programmed cell death, in malignant cells by blocking the expression of essential oncogenes.

Keywords:
AntisenseApoptosisBCL-2Lymphoma

More Related Videos

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

14.5K
Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
07:47

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

19.9K

Related Experiment Videos

Last Updated: Mar 18, 2026

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids
09:04

Sequence-specific and Selective Recognition of Double-stranded RNAs over Single-stranded RNAs by Chemically Modified Peptide Nucleic Acids

Published on: September 21, 2017

10.0K
Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts
07:02

Evaluation of Exon Inclusion Induced by Splice Switching Antisense Oligonucleotides in SMA Patient Fibroblasts

Published on: May 11, 2018

14.5K
Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System
07:47

Intrathecal Delivery of Antisense Oligonucleotides in the Rat Central Nervous System

Published on: October 29, 2019

19.9K

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Most lymphomas originate from B-cells, often involving translocations near the immunoglobulin heavy chain (IGH) gene.
  • Normal B-cell development requires IGH gene rearrangement, a process susceptible to errors leading to B-cell lymphomas.
  • Current treatments for lymphoma lack specificity and struggle to induce apoptosis in malignant cells.

Purpose of the Study:

  • To explore the potential of antisense oligonucleotides (ASO) as a targeted therapy for malignant lymphoma.
  • To investigate the mechanism by which ASO can induce apoptosis in cancer cells.

Main Methods:

  • ASO therapy utilizes short DNA sequences complementary to aberrant mRNA in tumor cells.
  • This complementary binding forms an mRNA-DNA duplex, inhibiting protein translation.
  • The specificity of oligonucleotide binding to mRNA is a key aspect of the methodology.

Main Results:

  • ASO therapy has the potential to 'switch off' oncogenes driving lymphoma proliferation.
  • By blocking essential protein production, ASO can negate the malignant potential of cancer cells.
  • Successful gene expression inhibition using oligonucleotides has been demonstrated previously.

Conclusions:

  • Antisense oligonucleotide therapy presents a promising strategy for treating B-cell lymphomas.
  • Targeting specific gene expression with ASO can lead to the induction of apoptosis in malignant cells.
  • This approach offers a molecularly targeted alternative to conventional lymphoma treatments.